RDA Financial Network Increases Stake in Eli Lilly and Company $LLY

Posted by Geri Gentry on Aug 4th, 2026

Eli Lilly and Company logo RDA Financial Network increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 40.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,517 shares of the company’s stock after acquiring an additional 1,295 shares during the period. Eli Lilly and Company makes up 1.2% of RDA Financial Network’s investment portfolio, making the stock its 17th largest position. RDA Financial Network’s holdings in Eli Lilly and Company were worth $5,418,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Schnieders Capital Management LLC. raised its position in shares of Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new position in Eli Lilly and Company in the second quarter valued at $356,000. Finally, Nebula Research & Development LLC acquired a new position in Eli Lilly and Company in the second quarter valued at $749,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Citigroup lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Bank of America increased their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

Get Our Latest Research Report on LLY

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly plans to provide limited early access to experimental obesity drug retatrutide before potential U.S. FDA approval. The next-generation therapy could strengthen Lilly’s leadership in the rapidly expanding obesity market, although early access does not guarantee regulatory approval. Eli Lilly to offer early access to next-gen obesity drug to some patients
Positive Sentiment: The FDA granted Breakthrough Therapy designation to olomorasib for previously treated patients with advanced pancreatic cancer carrying KRAS G12C mutations. The designation may accelerate development and regulatory review of Lilly’s investigational cancer treatment, expanding its pipeline beyond diabetes and obesity. Lilly’s olomorasib receives FDA Breakthrough Therapy designation
Positive Sentiment: Investor attention remains focused on strong demand for Mounjaro and Zepbound, which are expected to drive second-quarter revenue and earnings growth. Lilly’s recent results showed rapid year-over-year expansion, while several analysts maintain price targets above current trading levels. Will Mounjaro and Zepbound Drive Lilly’s Q2 Results
Neutral Sentiment: LLY is approaching a major earnings catalyst. Market commentary points to potential upside if sales exceed expectations but also warns that the stock could experience a large move in either direction because strong growth expectations are already embedded in its valuation. Eli Lilly Could Swing Over $76 Billion in Value After Earnings
Negative Sentiment: Valuation analyses suggest the stock may be priced above estimates of its cash-flow-based intrinsic value after rising more than 300% over five years. This raises the bar for earnings, guidance and future obesity-drug growth. Eli Lilly Stock Looks Below Fair Value on Cash Flow
Negative Sentiment: Novo Nordisk is attempting to regain momentum in the obesity-drug race, potentially increasing pricing and market-share pressure on Lilly. Separately, an executive’s recent open-market sale provides a modest negative sentiment signal, though it does not establish a change in company fundamentals. Obesity battle heats up as Novo competes with Lilly

Eli Lilly and Company Trading Down 2.3%

Shares of LLY opened at $1,122.32 on Tuesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45. The stock’s 50-day moving average is $1,153.77 and its two-hundred day moving average is $1,044.22. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market cap of $1.06 trillion, a PE ratio of 39.87, a P/E/G ratio of 1.43 and a beta of 0.51.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.